Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer 

Protocol Documents

Protocol-ACRIN 6682 Amendment 3, v3.1.13 [PDF] 

SOC-ACRIN 6682 Amendment 3, v3.1.13 [PDF]

Informed Consent-ACRIN 6682 [DOC]

Cu-64 ATSM Investigator's Brochure Version 2.0, 8.24.10 [PDF]

Principal Investigator:  Farrokh Dehdashti, MD

Status:  In follow-up

Main Objective: The objective of this study is to determine whether 64CU-ATSM
used with PET/CT can distinguish patients with poorer survival outcomes from those
with better survival outcomes prior to initiation of therapy.

Participants: Women with stages IB2–IVA, histologically confirmed, invasive squamous
cell cervical carcinoma, who are scheduled to undergo radiation therapy and concurrent
cisplatin chemotherapy.

Study Design Summary: A total of 100 female participants will be enrolled into the study
at a minimum of three (3) institutions.